The TNBC Forum for Drug Developers Accelerating Therapies to Patients With the Niche Aggressive TNBC Tumor Type
Welcome to the Triple Negative Breast Cancer (TNBC) Drug Development Digital Summit!
With breast cancer being the leading cause of cancer death amongst women ages 35 – 54 in the US, there is a huge unmet medical need. The Triple Negative Breast Cancer Drug Development Summit has been curated as we strive to deliver unprecedented clinical progress in this aggressive breast cancer through the development of checkpoint, PARP, CDK, ATR inhibitors, ADCs and other treatment modalities.
Join leading experts from CytoDyn, Zenith Epigenetics, Oncorus, Univeristy of Pittsburgh and more who are identifying specific molecular targets, such as immune checkpoint modulators, intra-nuclear targets, intracellular targets, and cell surface targets, to limit the progression and metastasis of this invasive tumor and improve patient outcomes.
Whether you are developing a TROP2-ADC, a PARP inhibitor, a viral immunotherapy or a cancer vaccine for treating TNBC, this dedicated digital meeting is your opportunity to discuss novel, cutting edge targeted therapies in TNBC and get a full picture of the clinical landscape.
Join Industry Leaders to:
Discuss what biomarkers will be the most predictive in determining which treatment option is best for patients and how this can inform the treatment regime
Analyze the latest immunotherapy approaches to understand how to improve the response rate by inducing anti-tumor immunity
Learn how to optimize the best combinatorial therapies to improve the complete pathology response rate
Hear how oncolytic viruses can be engineered to increase the immune response and create T cell infiltration into the tumor